Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Maria Shellock"'
Autor:
Lauren Scarpetti, Chetan C Oturkar, Dejan Juric, Maria Shellock, Giuliana Malvarosa, Kathryn Post, Steven Isakoff, Nancy Wang, Brian Nahed, Kevin Oh, Gokul M Das, Aditya Bardia
Publikováno v:
The Oncologist. 28:358-363
The absence of effective therapeutic targets and aggressive nature of triple-negative breast cancer (TNBC) renders this disease subset difficult to treat. Although estrogen receptor beta (ERβ) is expressed in TNBC, studies on its functional role hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae56fdd7dfec2f20a3f96176eb1acb3e
https://doi.org/10.1093/oncolo/oyac281
https://doi.org/10.1093/oncolo/oyac281
Autor:
Aditya Bardia, James T. Coates, Laura Spring, Sheng Sun, Dejan Juric, Nayana Thimmiah, Andrzej Niemierko, Phoebe Ryan, Ann Partridge, Jeffrey Peppercorn, Heather Parsons, Seth Wander, Kelsey Pierce, Victoria Attaya, Donna Fitzgerald, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Bev Moy, Sara Tolaney, Leif Ellisen
Publikováno v:
Cancer Research. 82:2638-2638
Background: Sacituzumab Govitecan (SG), the first antibody-drug conjugate approved for metastatic TNBC (mTNBC), is comprised of SN-38 (active metabolite of irinotecan), a topoisomerase I (TOP1) inhibitor, coupled via a hydrolyzable linker to monoclon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b60ae80d4c9fa6ffa289395bce0b42b
https://doi.org/10.1158/1538-7445.am2022-2638
https://doi.org/10.1158/1538-7445.am2022-2638
Autor:
Jennifer A. Chan, Lawrence S. Blaszkowsky, Kimmie Ng, Charles S. Fuchs, Pankaj Bhargava, Maria Shellock, Jill N. Allen, Jeffrey A. Meyerhardt, Brian M. Wolpin, Andrew X. Zhu, Nadine Jackson McCleary, Eunice L. Kwak, Peter C. Enzinger, Meaghan Elliott, Wolfram Goessling, Deborah Schrag, Thomas A. Abrams, Eileen Regan
Publikováno v:
Journal of Clinical Oncology. 30:560-560
560 Background: Everolimus (E) is an oral inhibitor of mTOR. Tivozanib (T) is a highly potent, selective, oral inhibitor of VEGF receptors-1, -2, and -3. Preclinical data suggest antitumor activity for this combination in colorectal cancer. We theref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff90045a5e36e2701bc19d9eae98f254
https://doi.org/10.1200/jco.2012.30.4_suppl.560
https://doi.org/10.1200/jco.2012.30.4_suppl.560